Your browser is no longer supported. Please, upgrade your browser.
PTCT PTC Therapeutics, Inc. daily Stock Chart
PTCT [NASD]
PTC Therapeutics, Inc.
Index- P/E- EPS (ttm)-6.91 Insider Own0.30% Shs Outstand65.15M Perf Week-5.66%
Market Cap3.50B Forward P/E- EPS next Y-3.44 Insider Trans-74.48% Shs Float62.07M Perf Month13.31%
Income-431.80M PEG- EPS next Q-0.03 Inst Own99.32% Short Float8.33% Perf Quarter8.53%
Sales311.40M P/S11.24 EPS this Y-55.40% Inst Trans0.55% Short Ratio7.58 Perf Half Y3.52%
Book/sh8.79 P/B5.86 EPS next Y37.70% ROA-27.50% Target Price61.18 Perf Year41.16%
Cash/sh7.34 P/C7.02 EPS next 5Y-9.51% ROE-73.20% 52W Range30.79 - 59.89 Perf YTD7.25%
Dividend- P/FCF- EPS past 5Y-7.50% ROI-27.80% 52W High-13.99% Beta1.22
Dividend %- Quick Ratio2.90 Sales past 5Y64.80% Gross Margin94.90% 52W Low67.28% ATR1.96
Employees754 Current Ratio3.00 Sales Q/Q-12.00% Oper. Margin- RSI (14)54.45 Volatility3.29% 3.71%
OptionableYes Debt/Eq0.60 EPS Q/Q-272.60% Profit Margin- Rel Volume0.27 Prev Close52.09
ShortableYes LT Debt/Eq0.56 EarningsOct 29 AMC Payout- Avg Volume681.90K Price51.51
Recom2.00 SMA203.04% SMA505.25% SMA2003.59% Volume181,455 Change-1.11%
Oct-07-20Upgrade JP Morgan Neutral → Overweight $71
Aug-25-20Initiated Raymond James Outperform $63
Apr-09-20Upgrade Citigroup Neutral → Buy $71 → $67
Feb-20-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-20-20Downgrade Citigroup Buy → Neutral $55 → $71
Nov-12-19Initiated SunTrust Buy $78
May-13-19Upgrade BofA/Merrill Neutral → Buy $43 → $49
Apr-11-19Initiated Bernstein Outperform $48
Oct-03-18Upgrade BofA/Merrill Underperform → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $66
Jul-19-18Initiated Credit Suisse Outperform $49
Jun-18-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-04-18Downgrade Barclays Equal Weight → Underweight $24 → $26
Jan-29-18Resumed RBC Capital Mkts Sector Perform
Nov-16-17Upgrade JP Morgan Underweight → Neutral
Oct-26-17Downgrade BofA/Merrill Neutral → Underperform
Oct-09-17Downgrade JP Morgan Neutral → Underweight
Sep-29-17Reiterated RBC Capital Mkts Sector Perform
Sep-29-17Reiterated Barclays Equal Weight $22 → $15
Aug-23-17Initiated William Blair Mkt Perform
Oct-20-20 12:58PM  
Oct-15-20 08:00AM  
Sep-28-20 01:00AM  
Sep-25-20 04:30PM  
Sep-24-20 08:00AM  
Sep-15-20 11:02AM  
Sep-14-20 03:20PM  
Sep-09-20 08:00AM  
Sep-08-20 08:00AM  
Sep-03-20 08:00AM  
Aug-27-20 09:39AM  
Aug-26-20 09:44AM  
08:00AM  
Aug-21-20 04:30PM  
Aug-18-20 05:07PM  
Aug-17-20 08:00AM  
Aug-10-20 07:07AM  
Aug-08-20 10:40AM  
Aug-07-20 02:46PM  
01:54PM  
Aug-06-20 08:00AM  
Aug-05-20 06:15PM  
04:01PM  
Jul-29-20 12:33PM  
Jul-22-20 08:00AM  
Jul-21-20 09:00AM  
Jul-20-20 07:45AM  
07:30AM  
Jul-12-20 08:14PM  
Jul-08-20 08:00AM  
Jun-29-20 02:04PM  
08:00AM  
Jun-23-20 04:05PM  
Jun-18-20 05:53PM  
10:25AM  
10:16AM  
Jun-17-20 07:30AM  
06:30AM  
Jun-12-20 04:30PM  
04:15PM  
Jun-10-20 08:00AM  
Jun-08-20 02:47AM  
Jun-01-20 08:00AM  
May-28-20 09:00AM  
May-27-20 07:04PM  
May-26-20 08:00AM  
May-21-20 04:27PM  
May-15-20 04:30PM  
May-06-20 04:30PM  
May-05-20 08:00AM  
Apr-30-20 06:35PM  
Apr-28-20 01:00AM  
Apr-23-20 12:32PM  
Apr-22-20 04:30PM  
Apr-17-20 08:00AM  
Apr-16-20 08:00AM  
Apr-09-20 10:16AM  
Apr-07-20 04:05PM  
Mar-30-20 06:06PM  
Mar-29-20 12:32PM  
Mar-25-20 09:04AM  
Mar-16-20 08:00AM  
Mar-11-20 04:30PM  
Mar-10-20 11:53AM  
Mar-04-20 09:40AM  
Mar-02-20 05:25PM  
04:01PM  
Feb-25-20 04:30PM  
Feb-24-20 12:30PM  
Feb-18-20 08:00AM  
Feb-17-20 04:30PM  
Feb-06-20 04:08PM  
10:41AM  
05:00AM  
Feb-03-20 04:30PM  
08:05AM  
08:00AM  
Jan-23-20 08:51AM  
01:00AM  
Jan-13-20 08:00AM  
Jan-07-20 12:09PM  
Jan-06-20 08:00AM  
Dec-26-19 11:58AM  
Dec-19-19 10:09AM  
Dec-13-19 04:30PM  
Dec-04-19 10:23PM  
Dec-03-19 10:09AM  
Nov-29-19 04:30PM  
Nov-25-19 04:59PM  
Nov-21-19 11:22AM  
Nov-19-19 08:00AM  
Nov-18-19 08:00AM  
Nov-12-19 09:43AM  
Nov-11-19 01:00AM  
Nov-04-19 11:42PM  
Oct-31-19 04:30PM  
Oct-29-19 06:55PM  
04:01PM  
Oct-24-19 12:26PM  
08:00AM  
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SOUTHWELL DAVID PDirectorOct 16Option Exercise11.0227,000297,51016,650Oct 20 04:34 PM
Jacobson Allan StevenDirectorOct 16Sale51.295,000256,4503,498Oct 20 04:35 PM
SOUTHWELL DAVID PDirectorOct 16Sale51.5427,0001,391,5441,650Oct 20 04:34 PM
Peltz Stuart WalterChief Executive OfficerOct 07Option Exercise11.1171,104789,785104,260Oct 09 04:20 PM
Peltz Stuart WalterChief Executive OfficerOct 07Sale53.3871,1043,795,26256,085Oct 09 04:20 PM
Utter Christine MarieSVP, Finance & CAOOct 06Option Exercise18.012,50045,02512,062Oct 07 08:59 PM
Peltz Stuart WalterChief Executive OfficerOct 06Option Exercise11.01124,3511,368,902107,910Oct 07 09:01 PM
Peltz Stuart WalterChief Executive OfficerOct 06Sale50.12124,3516,233,08356,085Oct 07 09:01 PM
Utter Christine MarieSVP, Finance & CAOOct 06Sale50.082,500125,2089,562Oct 07 08:59 PM
Utter Christine MarieSVP, Finance & CAOOct 05Option Exercise11.237878,83810,349Oct 07 08:59 PM
Peltz Stuart WalterChief Executive OfficerOct 05Option Exercise10.8555,460601,741110,645Oct 07 09:01 PM
Peltz Stuart WalterChief Executive OfficerOct 05Sale50.0055,4602,773,00056,085Oct 07 09:01 PM
Utter Christine MarieSVP, Finance & CAOOct 05Sale48.6878738,3119,562Oct 07 08:59 PM
Peltz Stuart WalterChief Executive OfficerJul 15Option Exercise10.85100,0001,085,000106,085Jul 17 04:30 PM
Peltz Stuart WalterChief Executive OfficerJul 15Sale55.70100,0005,570,15156,085Jul 17 04:30 PM
Boulding Mark ElliottExec. VP and CLOJul 07Option Exercise15.1030,625462,56957,224Jul 09 04:08 PM
Boulding Mark ElliottExec. VP and CLOJul 07Sale55.1230,6251,688,03739,724Jul 09 04:08 PM
Utter Christine MarieSVP, Finance & CAOJul 06Option Exercise16.393,28853,87412,062Jul 08 04:04 PM
Utter Christine MarieSVP, Finance & CAOJul 06Sale53.703,288176,5649,562Jul 08 04:04 PM
Hill Emily LuisaChief Financial OfficerJun 29Sale52.502,581135,50313,610Jul 01 04:06 PM
Svoronos DawnDirectorJun 11Sale48.3636417,60326,286Jun 12 04:04 PM
Peltz Stuart WalterChief Executive OfficerMay 20Option Exercise10.8533,788366,60089,873May 22 04:05 PM
Peltz Stuart WalterChief Executive OfficerMay 20Sale50.0033,7881,689,40056,085May 22 04:05 PM
Peltz Stuart WalterChief Executive OfficerMay 18Option Exercise10.856,28468,18162,369May 20 04:07 PM
Peltz Stuart WalterChief Executive OfficerMay 18Sale50.126,284314,97956,085May 20 04:07 PM
Peltz Stuart WalterChief Executive OfficerMay 05Option Exercise10.85109,9281,192,719166,013May 07 03:44 PM
Peltz Stuart WalterChief Executive OfficerMay 05Sale50.34109,9285,533,59256,085May 07 03:44 PM
Jacobson Allan StevenDirectorApr 20Option Exercise10.8517,900194,21526,398Apr 21 04:13 PM
Jacobson Allan StevenDirectorApr 20Sale51.0417,900913,5588,498Apr 21 04:13 PM
Jacobson Allan StevenDirectorApr 17Option Exercise10.852,10022,78510,598Apr 21 04:13 PM
Utter Christine MarieSVP, Finance & CAOApr 17Option Exercise18.012,14538,63111,449Apr 21 04:15 PM
Jacobson Allan StevenDirectorApr 17Sale50.162,100105,3328,498Apr 21 04:13 PM
Utter Christine MarieSVP, Finance & CAOApr 17Sale50.002,145107,2509,304Apr 21 04:15 PM
Utter Christine MarieSVP, Finance & CAOApr 03Option Exercise11.237878,83810,091Apr 07 04:05 PM
Utter Christine MarieSVP, Finance & CAOApr 03Sale44.3178734,8729,304Apr 07 04:05 PM
SCHMERTZLER MICHAELDirectorMar 16Buy32.4810,000324,846100,066Mar 18 05:05 PM
Souza MarcioChief Operating OfficerFeb 10Option Exercise12.926258,0757,369Feb 12 04:09 PM
Souza MarcioChief Operating OfficerFeb 10Sale53.9262533,7006,744Feb 12 04:09 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 06Option Exercise10.8550,000542,50073,987Feb 07 04:41 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 06Sale55.004,040222,2001,912Feb 07 04:41 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 06Sale55.0050,0002,750,00027,089Feb 07 04:41 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 05Sale55.0040522,2755,952Feb 07 04:41 PM
Hill Emily LuisaChief Financial OfficerJan 23Sale53.2533017,5726,891Jan 27 04:14 PM
Peltz Stuart WalterChief Executive OfficerJan 23Sale53.2542322,52318,102Jan 27 04:12 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 23Sale53.25462,4495,987Jan 27 04:09 PM
Souza MarcioChief Operating OfficerJan 23Sale53.251548,2005,074Jan 27 04:15 PM
Utter Christine MarieSVP, Finance & CAOJan 07Option Exercise15.7813,750216,95012,724Jan 08 06:07 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 07Sale49.62592,9286,033Jan 08 06:06 PM
Utter Christine MarieSVP, Finance & CAOJan 07Sale50.0213,750687,7335,224Jan 08 06:07 PM
Hill Emily LuisaChief Financial OfficerJan 07Sale49.62633,1267,221Jan 08 06:03 PM
Utter Christine MarieSVP, Finance & CAOJan 06Sale48.1736017,3405,224Jan 08 06:07 PM
Hill Emily LuisaChief Financial OfficerJan 06Sale48.1732115,4627,284Jan 08 06:03 PM
Souza MarcioChief Operating OfficerJan 06Sale48.17864,1425,228Jan 08 06:09 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 06Sale48.171276,1176,092Jan 08 06:06 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 06Sale48.1750724,42116,889Jan 08 06:06 PM
Peltz Stuart WalterChief Executive OfficerJan 06Sale48.1779838,43818,525Jan 08 06:04 PM
Peltz Stuart WalterChief Executive OfficerJan 06Sale48.171,79786,55823,085Jan 08 06:04 PM
Utter Christine MarieSVP, Finance & CAOJan 03Option Exercise11.237888,8496,372Jan 06 04:52 PM
Utter Christine MarieSVP, Finance & CAOJan 03Sale47.4278837,3675,584Jan 06 04:52 PM
Utter Christine MarieSVP, Finance & CAOJan 02Option Exercise11.232,36226,5257,946Jan 06 04:52 PM
Utter Christine MarieSVP, Finance & CAOJan 02Sale47.892,362113,1115,584Jan 06 04:52 PM
Souza MarcioChief Operating OfficerDec 23Option Exercise12.926,25080,75011,288Dec 26 05:24 PM
Souza MarcioChief Operating OfficerDec 23Option Exercise14.4275,8811,094,54468,221Dec 26 05:24 PM
Souza MarcioChief Operating OfficerDec 23Sale48.806,250305,0005,038Dec 26 05:24 PM
Souza MarcioChief Operating OfficerDec 23Sale48.9096,6954,728,73238,221Dec 26 05:24 PM
Peltz Stuart WalterChief Executive OfficerDec 03Option Exercise13.9718,981265,16926,332Dec 05 04:50 PM
Peltz Stuart WalterChief Executive OfficerDec 03Sale50.0022,4631,123,15018,676Dec 05 04:50 PM